Study #2024-0167
A randomized, open-label phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of Naporafenib + Trametinib to physician's choice of therapy (Dacarbazine, Temozolomide or Trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2]
MD Anderson Study Status
Not Accepting
Treatment Agent
Naporafenib, Trametinib, Dacarbazine, Temozolomide
Description
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic NRAS-mutant Melanoma
Study phase:
Phase III
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-866-478-2259
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.